Plant-Produced Recombinant Humaninterleukin-2
Print
EmailRecombinant human interleukin-2 (rhIL-2) is a biopharmaceutical protein of great importance, asit is the standard FDA-approved immunotherapeutic treatment for end-stage metastatic melanomaand renal cell cancer.
Find out more about this topic in this article.
Did you find this article useful?
You Might Also Be Interested In
-
Reciprocal Research: A Guidebook to Centering Community in Partnerships with Indigenous Nations
Published on April 22, 2021
-
MSU researcher awarded five-year, $2.5 million grant to develop risk assessment training program
Published on October 13, 2020
-
MSU Product Center helps Michigan food entrepreneurs survive and thrive throughout pandemic
Published on August 31, 2021
-
Protecting Michigan’s environment and wildlife through the Conservation Reserve Enhancement Program
Published on September 1, 2021
-
MSU Extension to undertake three-year, $7 million vaccination education effort
Published on August 17, 2021
